These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17285226)

  • 61. Daily activity performance in congenital and childhood forms of myotonic dystrophy type 1: a population-based study.
    Eriksson BM; Ekström AB; Peny-Dahlstrand M
    Dev Med Child Neurol; 2020 Jun; 62(6):723-728. PubMed ID: 31701525
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Does abnormal neuronal excitability exist in myotonic dystrophy? II. Effects of the antiarrhythmic drug hydroquinidine on apathy and hypersomnia.
    Di Costanzo A; Mottola A; Toriello A; Di Iorio G; Tedeschi G; Bonavita V
    Neurol Sci; 2000 Apr; 21(2):81-6. PubMed ID: 10938185
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Understanding the experience of myotonic dystrophy. Mixed method study.
    Geirdal AØ; Lund-Petersen I; Heiberg A
    J Genet Couns; 2015 Feb; 24(1):169-78. PubMed ID: 25123360
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy.
    Sugino M; Ohsawa N; Ito T; Ishida S; Yamasaki H; Kimura F; Shinoda K
    Neurology; 1998 Aug; 51(2):586-9. PubMed ID: 9710041
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Demystifying the effect of modafinil in epilepsy.
    Garcia VA; Matos G; Tufik S; Scorza FA; Cavalheiro EA; Schröder N; Andersen ML
    Epilepsy Behav; 2012 Jun; 24(2):287. PubMed ID: 22559984
    [No Abstract]   [Full Text] [Related]  

  • 66. Baclofen trial in six myotonic dystrophy patients.
    Guilleminault C; Flagg WH; Coburn SC; Dement WC
    Acta Neurol Scand; 1978 Mar; 57(3):232-8. PubMed ID: 352086
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of myotonic dystrophy with tricyclics.
    Brumback RA; Carlson KM
    Muscle Nerve; 1983; 6(3):233-4. PubMed ID: 6855807
    [No Abstract]   [Full Text] [Related]  

  • 68. Living with myotonic dystrophy; what can be learned from couples? A qualitative study.
    Cup EH; Kinébanian A; Satink T; Pieterse AJ; Hendricks HT; Oostendorp RA; van der Wilt GJ; van Engelen BG
    BMC Neurol; 2011 Jul; 11():86. PubMed ID: 21752270
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The risks of using non-specific outcome measures to capture activities of daily living in myotonic dystrophy type 2.
    Hamadeh T; Bovenkerk DSH; Faber CG; Merkies ISJ
    Neuromuscul Disord; 2021 Apr; 31(4):367-368. PubMed ID: 33741224
    [No Abstract]   [Full Text] [Related]  

  • 70. The risks of using non-specific outcome measures to capture activities of daily living in myotonic dystrophy type 2 - Response.
    On Behalf Of All Authors ; Montagnese F; Schoser B
    Neuromuscul Disord; 2021 Apr; 31(4):369. PubMed ID: 33741229
    [No Abstract]   [Full Text] [Related]  

  • 71. "Slow" myotonic discharges.
    Barkhaus PE; Nandedkar SD
    Muscle Nerve; 2006 Dec; 34(6):799-800. PubMed ID: 16927341
    [No Abstract]   [Full Text] [Related]  

  • 72. Rhythm management in myotonic dystrophy: Progress has been made, but unsettled issues remain.
    Groh WJ
    Heart Rhythm; 2018 Jul; 15(7):969-970. PubMed ID: 29625279
    [No Abstract]   [Full Text] [Related]  

  • 73. Membership of a patients' association and well-being. A study into the relationship between membership of a patients' association, fellow-patient contact, information received, and psychosocial well-being of people with a neuromuscular disease.
    van Haastregt JC; de Witte LP; Terpstra SJ; Diederiks JP; van der Horst FG; de Geus CA
    Patient Educ Couns; 1994 Oct; 24(2):135-48. PubMed ID: 7746763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.
    LoRusso S; Weiner B; Arnold WD
    Neurotherapeutics; 2018 Oct; 15(4):872-884. PubMed ID: 30341596
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Measuring Habitual Physical Activity in Neuromuscular Disorders: A Systematic Review.
    Jimenez-Moreno AC; Newman J; Charman SJ; Catt M; Trenell MI; Gorman GS; Hogrel JY; Lochmüller H
    J Neuromuscul Dis; 2017; 4(1):25-52. PubMed ID: 28269791
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Myotonic disorders: A review article.
    Hahn C; Salajegheh MK
    Iran J Neurol; 2016 Jan; 15(1):46-53. PubMed ID: 27141276
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Psychostimulants and cognition: a continuum of behavioral and cognitive activation.
    Wood S; Sage JR; Shuman T; Anagnostaras SG
    Pharmacol Rev; 2014; 66(1):193-221. PubMed ID: 24344115
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Myotonia congenita and myotonic dystrophy: surveillance and management.
    Conravey A; Santana-Gould L
    Curr Treat Options Neurol; 2010 Jan; 12(1):16-28. PubMed ID: 20842486
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.
    de Vries JM; Hagemans ML; Bussmann JB; van der Ploeg AT; van Doorn PA
    Cell Mol Life Sci; 2010 Mar; 67(5):701-13. PubMed ID: 20196238
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.
    Lehmann-Horn F; Jurkat-Rott K; Rüdel R;
    Acta Myol; 2008 Dec; 27(3):98-113. PubMed ID: 19472919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.